

To: All Campus

From: Joseph Vitale, Chief Human Resources Officer  
Tom Schiltz, Director of Compensation and Benefits  
Marion Burnworth, Benefits Representative

Date: May 11, 2023

Re: Rx Updates - Additions to CVS Caremark effective July 1, 2023

---

We are delighted to share some exciting news regarding our ongoing efforts in the Department of Human Resources to enhance the College's benefit programs for all of you. Our aim is to identify cost-effective enhancements that will be highly appealing and valuable to our faculty and staff members.

Over the past several months, we have consulted with CVS Caremark to thoroughly review our existing formulary plan. We were successfully able to identify some significant changes, within budget, that will specifically benefit plan participants in terms of diabetes care. We couldn't be happier about this outcome!

- **Starting from July 1, 2023**, we are thrilled to announce the following positive changes that will come into effect:
- **Insulin:** The College will cover the full cost of insulin of individuals enrolled on our plan. Insulin will be added to CVS Caremark's preventive drug list. The member responsibility for insulin will become \$0 and will not be subject to the deductible. Providing diabetes medications with low or no cost-sharing has been shown to increase medication adherence and results in better long-term health outcomes.
- **Disposable Insulin Pumps (DIPs) and Continuous Glucose Monitors (CGMs):** CVS Caremark's Utilization Management Program will review the appropriateness of pumps and monitors based on clinical evidence.
- **Atopic Dermatitis (AD) and Rheumatoid Arthritis (RA):** Specialty Guideline Management will be added for medications used to treat these conditions. With the combination of the rise in prevalence and a broader array of treatments, this new program will ensure the therapeutic appropriateness of these medications, based on evidence-based medicine. This will include the use of Step Therapy (trying generics first when appropriate) and quantity limits during Step Therapy to reduce waste.
- **Auvi-Q and Xyrem:** Clinical oversight will be added to fills of Auvi-Q and Xyrem (epinephrine injection pens) to safeguard against unnecessary utilization.

- **Antidiabetic Agents:** To help address growing trend and off-label use of antidiabetic GLP- 1 (e.g., Ozempic, Victoza) and GIP/GLP-1 agonist agents (i.e., Mounjaro) including sodium- glucose cotransporter-2 (SGLT2) inhibitors, Prior Authorization (PA) will apply to fills of these medications. To minimize disruption, CVS Caremark's claim system will apply smart logic using diagnosis codes and prescription claims history to bypass the PA requirements. Claims rejected for PA, confirmation diagnosis of type 2 diabetes will be required for approval.

We sincerely believe that these modifications will greatly contribute to the overall well-being of our plan participants and provide enhanced support for managing diabetes. We are truly excited to share this news with you as it reflects our commitment to constantly improving and evolving our benefit programs to meet the needs of our faculty and staff.

If you have any questions or need further information, please don't hesitate to reach out to the Department of Human Resources. We are here to assist you and share all the necessary details.

Thank you for your continued dedication and hard work. We look forward to supporting your well-being and success.